Pallavi Jha, New Delhi: Leading vaccine manufacturer Bharat Biotech has announced that it has successfully developed Covicin, India’s first vaccine candidate for COVID-19 in association with Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).
Human trials for this potential coronavirus vaccine will start next month.
A statement issued by the company said that the SARS-COV-2 strain was isolated at the NIV based in Pune and transferred to Bharat Biotech. The domestic, inactivated vaccine was developed and manufactured at Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment Facility located in Gnome Valley, Hyderabad.
The Drug Controller General of India, Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare have given permission to start the Phase 1 and Phase 2 human clinical trials. Prior to this, the company had submitted the results obtained from pre-clinical studies.
“We are proud to announce India’s first domestically developed vaccine, Kovaxin, against Kovid-19. ICMR and NIV have been instrumental in the development of this vaccine. The project was approved with the active support and guidance of CDSCO. Our R&D and manufacturing teams worked tirelessly towards this platform in the deployment of our own technologies,” Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said.